Loading...
StocksRunner logo
 
 
Ascendis Pharma A/S
90.45
-1.92%
 
ASND Ascendis Pharma A/S Ameri
Last Price
Change
90.45
 
-1.92%
 
 
 

 
Sentiment
 
  Login to display
 
 

76.98

108.23

124.08

91.09

 
 
1m
3m
6m
1y
 

Summary

  Login to display Ascendis Pharma A/S Ameri (ASND) recommendation from the last 90 days from financial news and social media.
 

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

 
 

Risk Level

 
StocksRunner
 

Ascendis Pharma A/S Ameri (ASND) has Moderate Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

NA
 
 
 

Rating

×
 

Rating

5.00
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

4.00
 

StocksRunner

 Price value has negative momentum

 

Activity

×
 

Activity

1.86
 
 

Future

×
 

Future

4.00
 

StocksRunner

 Outperform the market

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
46%
100%
100%
100%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is unimpressive but have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
46%
54%
Positive
Negative
6 out of 13
events present
7 out of 13
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
2 Month Ago
82.86
+1.94%
 
Top Headlines

wedbush maintains ascendis pharma a (asnd) outperform recommendation. fintel reports that on june 2 2023 wedbush maintained coverage of ascendis pharma a (nasdaq:asnd) with a outperform recommendation.

Fri Jun 2, 2023

Potential

cantor fitzgerald reiterates ascendis pharma a (asnd) overweight recommendation. fintel reports that on june 1 2023 cantor fitzgerald reiterated coverage of ascendis pharma a (nasdaq:asnd) with a overweight recommendation.

Thu Jun 1, 2023

Rating

wedbush maintains ascendis pharma a (asnd) outperform recommendation. fintel reports that on may 8 2023 wedbush maintained coverage of ascendis pharma a (nasdaq:asnd) with a outperform recommendation.

Mon May 8, 2023

Potential

ascendis pharma q1 earnings: skytrofa soars pth hurdles yet to clear.

Tue May 2, 2023

Momentum

fda rejects ascendis pharmas transcon pth for hypoparathyroidism. thea complete response letter (crl) for) transco

Mon May 1, 2023

Activity

United States fda declines to approve ascendis hormone disorder therapy. denmark-based ascendis pharma a/s said on monday the United States food & drug administration had declined to approve its experimental therapy to treat adult patients with

Mon May 1, 2023

Activity

United States fda declines to approve ascendis hormone disease therapy. denmark-based ascendis pharma a/s said on monday the United States food & drug administration (fda) had declined to approve its experimental therapy to treat adult patients

Mon May 1, 2023

Activity

ascendis pharma: fda issues crl for transcon pth new drug application. (rttnews) - ascendis pharma a/s (asnd) announced the fda has issued a complete response letter for the transcon pth new drug application for the treatment of adults with hypo

Mon May 1, 2023

Activity
Activity

relative strength alert for ascendis pharma. legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful. one way we can try to measure the level of fear in a given stock is through a

Fri Apr 28, 2023

Potential

hc wainwright & co. maintains ascendis pharma a (asnd) buy recommendation. fintel reports that on april 18 2023 hc wainwright &. co. maintained coverage of ascendis

Wed Apr 19, 2023

Rating

rosen global investor counsel encourages ascendis pharma investors to inquire about securities class action investigation – asnd. ) resulting from allegations that ascendis may have issued mater

Mon Apr 17, 2023

Activity

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily ASND alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

ASND Ascendis Pharma A/S Ameri

Last Price
90.45
Change
-1.92%
 

Summary

  Login to display Ascendis Pharma A/S Ameri (ASND) recommendation from the last 90 days from financial news and social media.

 
 
76.98
108.23
124.08
91.09
 
 
1m
3m
6m
1y
 
Sentiment
 

  Login to display

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
100%
100%
100%
On Track
On Track
On Track
 
46%
54%
Positive
Negative
6 out of 13
events present
7 out of 13
events present
 

Street Opinion

Street view is unimpressive but have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

NA
 
 
 

Rating

×
 

Rating

5.00
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

4.00
 

StocksRunner

 Price value has negative momentum

 

Activity

×
 

Activity

1.86
 
 

Future

×
 

Future

4.00
 

StocksRunner

 Outperform the market

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

Ascendis Pharma A/S Ameri (ASND) has Moderate Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
2 Month Ago
82.86
+1.94%
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily ASND Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines